nodes	percent_of_prediction	percent_of_DWPC	metapath
Auranofin—PRDX5—embryo—muscle cancer	0.058	0.131	CbGeAlD
Auranofin—PRDX5—renal system—muscle cancer	0.0439	0.0992	CbGeAlD
Auranofin—PRDX5—cardiac atrium—muscle cancer	0.0393	0.0888	CbGeAlD
Auranofin—IKBKB—embryo—muscle cancer	0.0343	0.0776	CbGeAlD
Auranofin—PRDX5—tendon—muscle cancer	0.0343	0.0774	CbGeAlD
Auranofin—PRDX5—bone marrow—muscle cancer	0.0332	0.075	CbGeAlD
Auranofin—PRDX5—vagina—muscle cancer	0.0318	0.0718	CbGeAlD
Auranofin—PRDX5—head—muscle cancer	0.0294	0.0664	CbGeAlD
Auranofin—PRDX5—testis—muscle cancer	0.0284	0.0641	CbGeAlD
Auranofin—IKBKB—smooth muscle tissue—muscle cancer	0.027	0.061	CbGeAlD
Auranofin—IKBKB—tendon—muscle cancer	0.0203	0.0458	CbGeAlD
Auranofin—IKBKB—vagina—muscle cancer	0.0188	0.0425	CbGeAlD
Auranofin—IKBKB—head—muscle cancer	0.0174	0.0393	CbGeAlD
Auranofin—IKBKB—testis—muscle cancer	0.0168	0.038	CbGeAlD
Auranofin—Interstitial pneumonia—Etoposide—muscle cancer	0.0155	0.0374	CcSEcCtD
Auranofin—Interstitial lung disease—Etoposide—muscle cancer	0.0106	0.0256	CcSEcCtD
Auranofin—ALB—testis—muscle cancer	0.00981	0.0222	CbGeAlD
Auranofin—Aplastic anaemia—Dactinomycin—muscle cancer	0.00974	0.0235	CcSEcCtD
Auranofin—PRDX5—Cellular responses to stress—HMGA1—muscle cancer	0.00932	0.0654	CbGpPWpGaD
Auranofin—Interstitial pneumonia—Methotrexate—muscle cancer	0.0093	0.0224	CcSEcCtD
Auranofin—PRDX5—Selenium Micronutrient Network—PTGS2—muscle cancer	0.0086	0.0604	CbGpPWpGaD
Auranofin—IKBKB—Hair Follicle Development: Induction (Part 1 of 3)—TP63—muscle cancer	0.0072	0.0506	CbGpPWpGaD
Auranofin—Dysphagia—Dactinomycin—muscle cancer	0.00651	0.0157	CcSEcCtD
Auranofin—Interstitial lung disease—Methotrexate—muscle cancer	0.00635	0.0153	CcSEcCtD
Auranofin—Pancytopenia—Dactinomycin—muscle cancer	0.00618	0.0149	CcSEcCtD
Auranofin—Neutropenia—Dactinomycin—muscle cancer	0.00608	0.0147	CcSEcCtD
Auranofin—IKBKB—Validated transcriptional targets of TAp63 isoforms—TP63—muscle cancer	0.00589	0.0414	CbGpPWpGaD
Auranofin—Gingivitis—Methotrexate—muscle cancer	0.00573	0.0138	CcSEcCtD
Auranofin—Stomatitis—Dactinomycin—muscle cancer	0.00566	0.0136	CcSEcCtD
Auranofin—Pancytopenia—Vincristine—muscle cancer	0.00552	0.0133	CcSEcCtD
Auranofin—Neutropenia—Vincristine—muscle cancer	0.00544	0.0131	CcSEcCtD
Auranofin—Agranulocytosis—Dactinomycin—muscle cancer	0.00541	0.013	CcSEcCtD
Auranofin—IKBKB—Hair Follicle Development: Induction (Part 1 of 3)—PTCH1—muscle cancer	0.00539	0.0379	CbGpPWpGaD
Auranofin—IKBKB—Rac1/Pak1/p38/MMP-2 pathway—ANGPT2—muscle cancer	0.00527	0.037	CbGpPWpGaD
Auranofin—Weight decreased—Vincristine—muscle cancer	0.00526	0.0127	CcSEcCtD
Auranofin—Proteinuria—Methotrexate—muscle cancer	0.00512	0.0123	CcSEcCtD
Auranofin—IKBKB—BDNF signaling pathway—KIDINS220—muscle cancer	0.00511	0.0359	CbGpPWpGaD
Auranofin—Neuropathy peripheral—Vincristine—muscle cancer	0.00508	0.0122	CcSEcCtD
Auranofin—Stomatitis—Vincristine—muscle cancer	0.00505	0.0122	CcSEcCtD
Auranofin—Protein urine present—Methotrexate—muscle cancer	0.00505	0.0122	CcSEcCtD
Auranofin—Gingivitis—Doxorubicin—muscle cancer	0.00496	0.012	CcSEcCtD
Auranofin—Glossitis—Methotrexate—muscle cancer	0.00488	0.0118	CcSEcCtD
Auranofin—IKBKB—Apoptosis—TP73—muscle cancer	0.00481	0.0338	CbGpPWpGaD
Auranofin—Hepatic enzyme increased—Methotrexate—muscle cancer	0.00475	0.0115	CcSEcCtD
Auranofin—Dysphagia—Etoposide—muscle cancer	0.00471	0.0113	CcSEcCtD
Auranofin—Alopecia—Dactinomycin—muscle cancer	0.0046	0.0111	CcSEcCtD
Auranofin—Pancytopenia—Etoposide—muscle cancer	0.00447	0.0108	CcSEcCtD
Auranofin—Neutropenia—Etoposide—muscle cancer	0.0044	0.0106	CcSEcCtD
Auranofin—Melaena—Methotrexate—muscle cancer	0.00439	0.0106	CcSEcCtD
Auranofin—IKBKB—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—muscle cancer	0.00429	0.0301	CbGpPWpGaD
Auranofin—Glossitis—Doxorubicin—muscle cancer	0.00422	0.0102	CcSEcCtD
Auranofin—Aplastic anaemia—Methotrexate—muscle cancer	0.00422	0.0102	CcSEcCtD
Auranofin—Anaemia—Dactinomycin—muscle cancer	0.00419	0.0101	CcSEcCtD
Auranofin—IKBKB—Apoptosis—TP63—muscle cancer	0.00413	0.029	CbGpPWpGaD
Auranofin—Neuropathy peripheral—Etoposide—muscle cancer	0.00412	0.00992	CcSEcCtD
Auranofin—Alopecia—Vincristine—muscle cancer	0.00411	0.00991	CcSEcCtD
Auranofin—IKBKB—FoxO family signaling—FOXO4—muscle cancer	0.0041	0.0288	CbGpPWpGaD
Auranofin—Jaundice—Etoposide—muscle cancer	0.00409	0.00986	CcSEcCtD
Auranofin—Stomatitis—Etoposide—muscle cancer	0.00409	0.00986	CcSEcCtD
Auranofin—Leukopenia—Dactinomycin—muscle cancer	0.00406	0.00978	CcSEcCtD
Auranofin—Agranulocytosis—Etoposide—muscle cancer	0.00392	0.00944	CcSEcCtD
Auranofin—PRDX5—Cellular responses to stress—CDKN2A—muscle cancer	0.00382	0.0268	CbGpPWpGaD
Auranofin—Melaena—Doxorubicin—muscle cancer	0.0038	0.00916	CcSEcCtD
Auranofin—Anaemia—Vincristine—muscle cancer	0.00374	0.00902	CcSEcCtD
Auranofin—PRDX5—Cellular responses to stress—MDM2—muscle cancer	0.0037	0.026	CbGpPWpGaD
Auranofin—Aplastic anaemia—Doxorubicin—muscle cancer	0.00366	0.00881	CcSEcCtD
Auranofin—Leukopenia—Vincristine—muscle cancer	0.00363	0.00874	CcSEcCtD
Auranofin—Thrombocytopenia—Dactinomycin—muscle cancer	0.00362	0.00873	CcSEcCtD
Auranofin—Anorexia—Dactinomycin—muscle cancer	0.00353	0.0085	CcSEcCtD
Auranofin—Eye disorder—Etoposide—muscle cancer	0.00352	0.00849	CcSEcCtD
Auranofin—Dermatitis exfoliative—Methotrexate—muscle cancer	0.00346	0.00834	CcSEcCtD
Auranofin—IKBKB—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—muscle cancer	0.00338	0.0237	CbGpPWpGaD
Auranofin—Alopecia—Etoposide—muscle cancer	0.00333	0.00803	CcSEcCtD
Auranofin—Thrombocytopenia—Vincristine—muscle cancer	0.00324	0.0078	CcSEcCtD
Auranofin—IKBKB—AGE/RAGE pathway—FOXO4—muscle cancer	0.00323	0.0227	CbGpPWpGaD
Auranofin—Decreased appetite—Dactinomycin—muscle cancer	0.00322	0.00775	CcSEcCtD
Auranofin—Dysgeusia—Etoposide—muscle cancer	0.00321	0.00774	CcSEcCtD
Auranofin—Anorexia—Vincristine—muscle cancer	0.00315	0.00759	CcSEcCtD
Auranofin—Anaemia—Etoposide—muscle cancer	0.00303	0.00731	CcSEcCtD
Auranofin—IKBKB—FoxO family signaling—FOXO1—muscle cancer	0.00303	0.0213	CbGpPWpGaD
Auranofin—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00303	0.00729	CcSEcCtD
Auranofin—Dermatitis exfoliative—Doxorubicin—muscle cancer	0.003	0.00722	CcSEcCtD
Auranofin—IKBKB—Signaling by NGF—KIDINS220—muscle cancer	0.00295	0.0207	CbGpPWpGaD
Auranofin—Leukopenia—Etoposide—muscle cancer	0.00294	0.00708	CcSEcCtD
Auranofin—Abdominal pain—Dactinomycin—muscle cancer	0.00293	0.00705	CcSEcCtD
Auranofin—Decreased appetite—Vincristine—muscle cancer	0.00287	0.00693	CcSEcCtD
Auranofin—Constipation—Vincristine—muscle cancer	0.00283	0.00681	CcSEcCtD
Auranofin—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.00283	0.00681	CcSEcCtD
Auranofin—PRDX5—Cellular responses to stress—VEGFA—muscle cancer	0.00281	0.0198	CbGpPWpGaD
Auranofin—Eosinophilia—Methotrexate—muscle cancer	0.00279	0.00673	CcSEcCtD
Auranofin—Gastrointestinal pain—Vincristine—muscle cancer	0.0027	0.00651	CcSEcCtD
Auranofin—Pancytopenia—Methotrexate—muscle cancer	0.00268	0.00646	CcSEcCtD
Auranofin—Neutropenia—Methotrexate—muscle cancer	0.00264	0.00636	CcSEcCtD
Auranofin—Thrombocytopenia—Etoposide—muscle cancer	0.00262	0.00632	CcSEcCtD
Auranofin—Abdominal pain—Vincristine—muscle cancer	0.00261	0.0063	CcSEcCtD
Auranofin—Anorexia—Etoposide—muscle cancer	0.00255	0.00615	CcSEcCtD
Auranofin—Diarrhoea—Dactinomycin—muscle cancer	0.00253	0.0061	CcSEcCtD
Auranofin—Stomatitis—Methotrexate—muscle cancer	0.00245	0.00591	CcSEcCtD
Auranofin—Conjunctivitis—Methotrexate—muscle cancer	0.00244	0.00589	CcSEcCtD
Auranofin—Dysphagia—Doxorubicin—muscle cancer	0.00244	0.00589	CcSEcCtD
Auranofin—Eosinophilia—Doxorubicin—muscle cancer	0.00242	0.00583	CcSEcCtD
Auranofin—Haematuria—Methotrexate—muscle cancer	0.0024	0.00578	CcSEcCtD
Auranofin—IKBKB—AGE/RAGE pathway—FOXO1—muscle cancer	0.00239	0.0168	CbGpPWpGaD
Auranofin—IKBKB—Rac1/Pak1/p38/MMP-2 pathway—FOXO1—muscle cancer	0.00236	0.0166	CbGpPWpGaD
Auranofin—Vomiting—Dactinomycin—muscle cancer	0.00235	0.00567	CcSEcCtD
Auranofin—Agranulocytosis—Methotrexate—muscle cancer	0.00235	0.00566	CcSEcCtD
Auranofin—Rash—Dactinomycin—muscle cancer	0.00233	0.00562	CcSEcCtD
Auranofin—Decreased appetite—Etoposide—muscle cancer	0.00233	0.00561	CcSEcCtD
Auranofin—Pancytopenia—Doxorubicin—muscle cancer	0.00232	0.00559	CcSEcCtD
Auranofin—Constipation—Etoposide—muscle cancer	0.00229	0.00552	CcSEcCtD
Auranofin—Neutropenia—Doxorubicin—muscle cancer	0.00228	0.0055	CcSEcCtD
Auranofin—Diarrhoea—Vincristine—muscle cancer	0.00226	0.00545	CcSEcCtD
Auranofin—Weight decreased—Doxorubicin—muscle cancer	0.00221	0.00533	CcSEcCtD
Auranofin—Nausea—Dactinomycin—muscle cancer	0.0022	0.0053	CcSEcCtD
Auranofin—Gastrointestinal pain—Etoposide—muscle cancer	0.00219	0.00528	CcSEcCtD
Auranofin—Visual impairment—Methotrexate—muscle cancer	0.00218	0.00524	CcSEcCtD
Auranofin—IKBKB—Leptin signaling pathway—FOXO1—muscle cancer	0.00215	0.0151	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis—IGF2—muscle cancer	0.00214	0.015	CbGpPWpGaD
Auranofin—Neuropathy peripheral—Doxorubicin—muscle cancer	0.00213	0.00514	CcSEcCtD
Auranofin—Urticaria—Etoposide—muscle cancer	0.00213	0.00513	CcSEcCtD
Auranofin—PRDX5—Cellular responses to stress—TP53—muscle cancer	0.00212	0.0149	CbGpPWpGaD
Auranofin—Jaundice—Doxorubicin—muscle cancer	0.00212	0.00512	CcSEcCtD
Auranofin—Stomatitis—Doxorubicin—muscle cancer	0.00212	0.00512	CcSEcCtD
Auranofin—Abdominal pain—Etoposide—muscle cancer	0.00212	0.0051	CcSEcCtD
Auranofin—Conjunctivitis—Doxorubicin—muscle cancer	0.00212	0.0051	CcSEcCtD
Auranofin—Eye disorder—Methotrexate—muscle cancer	0.00211	0.00508	CcSEcCtD
Auranofin—Vomiting—Vincristine—muscle cancer	0.0021	0.00507	CcSEcCtD
Auranofin—Rash—Vincristine—muscle cancer	0.00208	0.00502	CcSEcCtD
Auranofin—Dermatitis—Vincristine—muscle cancer	0.00208	0.00502	CcSEcCtD
Auranofin—Haematuria—Doxorubicin—muscle cancer	0.00208	0.005	CcSEcCtD
Auranofin—Agranulocytosis—Doxorubicin—muscle cancer	0.00203	0.0049	CcSEcCtD
Auranofin—Alopecia—Methotrexate—muscle cancer	0.002	0.00481	CcSEcCtD
Auranofin—Nausea—Vincristine—muscle cancer	0.00196	0.00473	CcSEcCtD
Auranofin—Dysgeusia—Methotrexate—muscle cancer	0.00192	0.00464	CcSEcCtD
Auranofin—Pruritus—Etoposide—muscle cancer	0.00189	0.00457	CcSEcCtD
Auranofin—Visual impairment—Doxorubicin—muscle cancer	0.00188	0.00454	CcSEcCtD
Auranofin—Diarrhoea—Etoposide—muscle cancer	0.00183	0.00442	CcSEcCtD
Auranofin—Eye disorder—Doxorubicin—muscle cancer	0.00183	0.0044	CcSEcCtD
Auranofin—Anaemia—Methotrexate—muscle cancer	0.00182	0.00438	CcSEcCtD
Auranofin—Leukopenia—Methotrexate—muscle cancer	0.00176	0.00424	CcSEcCtD
Auranofin—IKBKB—B Cell Receptor Signaling Pathway—FOXO1—muscle cancer	0.00175	0.0123	CbGpPWpGaD
Auranofin—IKBKB—Validated transcriptional targets of TAp63 isoforms—CDKN2A—muscle cancer	0.00173	0.0122	CbGpPWpGaD
Auranofin—Alopecia—Doxorubicin—muscle cancer	0.00173	0.00416	CcSEcCtD
Auranofin—Vomiting—Etoposide—muscle cancer	0.0017	0.0041	CcSEcCtD
Auranofin—IKBKB—BDNF signaling pathway—CNR1—muscle cancer	0.0017	0.0119	CbGpPWpGaD
Auranofin—Rash—Etoposide—muscle cancer	0.00169	0.00407	CcSEcCtD
Auranofin—Dermatitis—Etoposide—muscle cancer	0.00169	0.00407	CcSEcCtD
Auranofin—IKBKB—Validated transcriptional targets of TAp63 isoforms—MDM2—muscle cancer	0.00168	0.0118	CbGpPWpGaD
Auranofin—Flatulence—Doxorubicin—muscle cancer	0.00168	0.00404	CcSEcCtD
Auranofin—Dysgeusia—Doxorubicin—muscle cancer	0.00167	0.00402	CcSEcCtD
Auranofin—Nausea—Etoposide—muscle cancer	0.00159	0.00383	CcSEcCtD
Auranofin—Anaemia—Doxorubicin—muscle cancer	0.00157	0.00379	CcSEcCtD
Auranofin—Thrombocytopenia—Methotrexate—muscle cancer	0.00157	0.00378	CcSEcCtD
Auranofin—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—FOXO4—muscle cancer	0.00154	0.0108	CbGpPWpGaD
Auranofin—Anorexia—Methotrexate—muscle cancer	0.00153	0.00368	CcSEcCtD
Auranofin—Leukopenia—Doxorubicin—muscle cancer	0.00152	0.00367	CcSEcCtD
Auranofin—IKBKB—Fc epsilon receptor (FCERI) signaling—FOXO4—muscle cancer	0.00147	0.0103	CbGpPWpGaD
Auranofin—Dyspepsia—Methotrexate—muscle cancer	0.00141	0.0034	CcSEcCtD
Auranofin—Decreased appetite—Methotrexate—muscle cancer	0.00139	0.00336	CcSEcCtD
Auranofin—Thrombocytopenia—Doxorubicin—muscle cancer	0.00136	0.00328	CcSEcCtD
Auranofin—IKBKB—B Cell Activation—FOXO4—muscle cancer	0.00136	0.00954	CbGpPWpGaD
Auranofin—Anorexia—Doxorubicin—muscle cancer	0.00132	0.00319	CcSEcCtD
Auranofin—Gastrointestinal pain—Methotrexate—muscle cancer	0.00131	0.00316	CcSEcCtD
Auranofin—Urticaria—Methotrexate—muscle cancer	0.00127	0.00307	CcSEcCtD
Auranofin—Abdominal pain—Methotrexate—muscle cancer	0.00127	0.00306	CcSEcCtD
Auranofin—Dyspepsia—Doxorubicin—muscle cancer	0.00122	0.00295	CcSEcCtD
Auranofin—IKBKB—Apoptosis—CDKN2A—muscle cancer	0.00122	0.00855	CbGpPWpGaD
Auranofin—Decreased appetite—Doxorubicin—muscle cancer	0.00121	0.00291	CcSEcCtD
Auranofin—Constipation—Doxorubicin—muscle cancer	0.00119	0.00286	CcSEcCtD
Auranofin—IKBKB—Apoptosis—MDM2—muscle cancer	0.00118	0.00829	CbGpPWpGaD
Auranofin—IKBKB—Insulin Signaling—FOXO1—muscle cancer	0.00118	0.00825	CbGpPWpGaD
Auranofin—ALB—Platelet degranulation—IGF2—muscle cancer	0.00118	0.00825	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis Modulation and Signaling—CDKN2A—muscle cancer	0.00114	0.00802	CbGpPWpGaD
Auranofin—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00114	0.00274	CcSEcCtD
Auranofin—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—FOXO1—muscle cancer	0.00114	0.00798	CbGpPWpGaD
Auranofin—Pruritus—Methotrexate—muscle cancer	0.00113	0.00273	CcSEcCtD
Auranofin—ALB—Response to elevated platelet cytosolic Ca2+—IGF2—muscle cancer	0.00112	0.00786	CbGpPWpGaD
Auranofin—Urticaria—Doxorubicin—muscle cancer	0.0011	0.00266	CcSEcCtD
Auranofin—Abdominal pain—Doxorubicin—muscle cancer	0.0011	0.00265	CcSEcCtD
Auranofin—Diarrhoea—Methotrexate—muscle cancer	0.0011	0.00264	CcSEcCtD
Auranofin—IKBKB—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	0.00108	0.00761	CbGpPWpGaD
Auranofin—Vomiting—Methotrexate—muscle cancer	0.00102	0.00246	CcSEcCtD
Auranofin—Rash—Methotrexate—muscle cancer	0.00101	0.00244	CcSEcCtD
Auranofin—Dermatitis—Methotrexate—muscle cancer	0.00101	0.00244	CcSEcCtD
Auranofin—IKBKB—B Cell Activation—FOXO1—muscle cancer	0.001	0.00705	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—FOXO4—muscle cancer	0.001	0.00702	CbGpPWpGaD
Auranofin—Pruritus—Doxorubicin—muscle cancer	0.000983	0.00237	CcSEcCtD
Auranofin—Nausea—Methotrexate—muscle cancer	0.000953	0.0023	CcSEcCtD
Auranofin—Diarrhoea—Doxorubicin—muscle cancer	0.00095	0.00229	CcSEcCtD
Auranofin—Vomiting—Doxorubicin—muscle cancer	0.000883	0.00213	CcSEcCtD
Auranofin—Rash—Doxorubicin—muscle cancer	0.000876	0.00211	CcSEcCtD
Auranofin—Dermatitis—Doxorubicin—muscle cancer	0.000875	0.00211	CcSEcCtD
Auranofin—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	0.000865	0.00608	CbGpPWpGaD
Auranofin—IKBKB—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.000826	0.0058	CbGpPWpGaD
Auranofin—Nausea—Doxorubicin—muscle cancer	0.000825	0.00199	CcSEcCtD
Auranofin—IKBKB—Rac1/Pak1/p38/MMP-2 pathway—TP53—muscle cancer	0.000812	0.0057	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—CD34—muscle cancer	0.000806	0.00566	CbGpPWpGaD
Auranofin—IKBKB—p75(NTR)-mediated signaling—TP53—muscle cancer	0.000793	0.00557	CbGpPWpGaD
Auranofin—IKBKB—B Cell Activation—KIT—muscle cancer	0.000764	0.00537	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—FOXO1—muscle cancer	0.000738	0.00519	CbGpPWpGaD
Auranofin—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.000681	0.00479	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis—TP53—muscle cancer	0.000678	0.00476	CbGpPWpGaD
Auranofin—IKBKB—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.000651	0.00457	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis Modulation and Signaling—TP53—muscle cancer	0.000636	0.00446	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—KIDINS220—muscle cancer	0.000634	0.00446	CbGpPWpGaD
Auranofin—IKBKB—B Cell Activation—MDM2—muscle cancer	0.000602	0.00423	CbGpPWpGaD
Auranofin—ALB—Selenium Micronutrient Network—PTGS2—muscle cancer	0.00058	0.00407	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—FOXO4—muscle cancer	0.00057	0.00401	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—KIT—muscle cancer	0.000563	0.00395	CbGpPWpGaD
Auranofin—ALB—Hemostasis—ANGPT2—muscle cancer	0.000553	0.00388	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—FOXO4—muscle cancer	0.000548	0.00385	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—IGF2—muscle cancer	0.000521	0.00366	CbGpPWpGaD
Auranofin—ALB—Platelet degranulation—VEGFA—muscle cancer	0.000493	0.00346	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CD34—muscle cancer	0.000489	0.00343	CbGpPWpGaD
Auranofin—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	0.000469	0.0033	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—MDM2—muscle cancer	0.000443	0.00311	CbGpPWpGaD
Auranofin—ALB—Folate Metabolism—TP53—muscle cancer	0.000434	0.00305	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—FOXO1—muscle cancer	0.000421	0.00296	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.00041	0.00288	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—FOXO1—muscle cancer	0.000404	0.00284	CbGpPWpGaD
Auranofin—IKBKB—MAPK Signaling Pathway—TP53—muscle cancer	0.000389	0.00273	CbGpPWpGaD
Auranofin—IKBKB—Immune System—FOXO4—muscle cancer	0.000332	0.00233	CbGpPWpGaD
Auranofin—ALB—Metabolism—FH—muscle cancer	0.000323	0.00227	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—KIT—muscle cancer	0.000321	0.00225	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—KIT—muscle cancer	0.000308	0.00216	CbGpPWpGaD
Auranofin—ALB—Hemostasis—IGF2—muscle cancer	0.000269	0.00189	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—MDM2—muscle cancer	0.000253	0.00178	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PTCH1—muscle cancer	0.00025	0.00175	CbGpPWpGaD
Auranofin—IKBKB—Immune System—FOXO1—muscle cancer	0.000245	0.00172	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—MDM2—muscle cancer	0.000243	0.0017	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	0.000219	0.00154	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—FOXO4—muscle cancer	0.000215	0.00151	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CNR1—muscle cancer	0.000211	0.00148	CbGpPWpGaD
Auranofin—IKBKB—Immune System—KIT—muscle cancer	0.000187	0.00131	CbGpPWpGaD
Auranofin—ALB—Metabolism—MED12—muscle cancer	0.000183	0.00128	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—IGF2—muscle cancer	0.000172	0.00121	CbGpPWpGaD
Auranofin—ALB—Metabolism—ENO2—muscle cancer	0.000167	0.00117	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—FOXO1—muscle cancer	0.000159	0.00111	CbGpPWpGaD
Auranofin—IKBKB—Immune System—MDM2—muscle cancer	0.000147	0.00103	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	0.00013	0.000915	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—KIT—muscle cancer	0.000121	0.000849	CbGpPWpGaD
Auranofin—ALB—Hemostasis—VEGFA—muscle cancer	0.000113	0.000791	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MDM2—muscle cancer	9.52e-05	0.000669	CbGpPWpGaD
Auranofin—ALB—Hemostasis—TP53—muscle cancer	8.51e-05	0.000598	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—VEGFA—muscle cancer	7.23e-05	0.000508	CbGpPWpGaD
Auranofin—ALB—Metabolism—PTGS2—muscle cancer	5.8e-05	0.000407	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TP53—muscle cancer	5.46e-05	0.000384	CbGpPWpGaD
